Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML

In this podcast, we bring you exclusive updates on acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.

You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia. 

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, The Christie NHS Foundation Trust, Manchester, UK, Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, and Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, will then go on to share updates on the use of menin inhibitors in relapsed/refractory (AML).

This will be followed by Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the management of FLT3-ITD+ AML.